

# Tivozanib


**SYN-1013**

1-(2-chloro-4-(6,7-dimethoxyquinolin-4-yloxy)phenyl)-3-(5-methylisoxazol-3-yl)urea

**CAS Registry No.:** 475108-18-0

**Smiles String:**

Cc1cc(no1)NC(=O)Nc2ccc(cc2Cl)Oc3ccnc4c3cc(c(c4)OC)OC



**Molecular Weight:** 454.86

**Molecular Formula:** C<sub>22</sub>H<sub>19</sub>ClN<sub>4</sub>O<sub>5</sub>

**Lot Number:** Refer to vial

**<sup>1</sup>H-NMR:** Available on request


**HPLC (Purity):** > 95.0% @ 254 nm

**ES-MS:** Available on request


## Description:

Tivozanib is a potent inhibitor of VEGFR-1, 2 & 3 (IC<sub>50</sub> 0.21, 0.16 and 0.24 nM respectively).

## Biological Activity



# Kinome Mapping



## Shipping and Storage Temperature

**Shipping:**  
Ambient

**Storage:**  
2 years -20C, Powder 1 month, -4C in DMSO, More than one month -80C in DMSO

## Solubility

DMSO 20mg/mL, Ethanol <1mg/mL

## Preparing Stock Solutions

| Stock Solution (1ml DMSO) | 1mM    | 10mM   | 20mM   | 50mM    |
|---------------------------|--------|--------|--------|---------|
| Mass(mg)                  | 0.4548 | 4.5486 | 9.0972 | 22.7430 |

## References

1. Eskens FA, de Jonge MJ, Bhargava P, Isoe T, Cotreau MM, Esteves B, Hayashi K, Burger H, Thomeer M, van Doorn L, Verweij J . Biologic and clinical activity of tivozanib (AV-951, KRN-951), a selective inhibitor of VEGF receptor-1, -2, and -3 tyrosine kinases, in a 4-week-on, 2-week-off schedule in patients with advanced solid tumors. Clin Cancer Res. 2011 Nov 15;17(22):7156-63. doi: 10.1158/1078-0432.CCR-11-0411. Epub 2011 Oct 5.

---

## Ordering Information

To order more of this or any other SYNkinase compound, go to [synkinase.com](http://synkinase.com), Call us Toll Free (US Only) at 1- 877-854-6273 or email [orders@synkinase.com](mailto:orders@synkinase.com).

Product Datasheet (Rev. 1.1)